[{"id":"7a2a3b4c-52cf-4f7d-afea-af8fd4a47657","acronym":"","url":"https://clinicaltrials.gov/study/NCT03650348","created_at":"2021-01-18T17:54:56.686Z","updated_at":"2024-07-02T16:35:08.258Z","phase":"Phase 1","brief_title":"PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors","source_id_and_acronym":"NCT03650348","lead_sponsor":"Pieris Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cinrebafusp alfa (PRS-343)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 08/11/2022","primary_completion_date":" 08/11/2022","study_txt":" Completion: 08/11/2022","study_completion_date":" 08/11/2022","last_update_posted":"2024-04-22"}]